In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Biospecifics Technologies (BSTC), with a price target of $90.00. The company’s shares closed last Monday at $53.67.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -15.5% and a 27.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and EyePoint Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biospecifics Technologies with a $90.00 average price target.
See today’s analyst top recommended stocks >>
Based on Biospecifics Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $6.27 million. In comparison, last year the company had a net profit of $5.04 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren’s contracture. The company was founded in 1990 and is headquartered in Lynbrook, NY.
